Evidence Level
Chamomile has demonstrated significant efficacy in addressing various health conditions, particularly generalized anxiety disorder (GAD). Amsterdam et al. (2009) conducted an 8-week randomized controlled trial (RCT) comparing chamomile extract to placebo, finding substantial reductions in Hamilton Anxiety Scale (HAM-A) scores among participants with GAD. This was further corroborated by Mao et al. (2016), who provided long-term data over 38 weeks, showing sustained anxiolytic effects and reduced relapse rates. Additionally, Amsterdam et al. (2012) highlighted chamomile's potential antidepressant activity in anxious, depressed individuals.
Recent studies have expanded on chamomile's benefits beyond anxiety. Kazemi et al. (2024) conducted a systematic review and meta-analysis of 10 clinical trials involving 772 participants, concluding that chamomile significantly improved sleep quality by reducing Pittsburgh Sleep Quality Index scores. Furthermore, Valmy et al. (2025) reviewed 11 randomized clinical trials, finding that chamomile exhibits anti-inflammatory effects, as evidenced by decreased mucositis severity and pain levels.
Chamomile's safety profile has also been extensively studied. Ostovar et al. (2025) analyzed 72 trials involving 2,896 participants and 11 case reports, concluding that chamomile is generally safe with minor adverse events such as gastrointestinal issues and drowsiness. However, allergic reactions were reported in six cases.
In summary, chamomile has robust evidence supporting its use for anxiety, sleep improvement, and anti-inflammatory effects, while maintaining a favorable safety profile.